Several case reports have described the success of targeted treatment to BRAF V600E-mutant brain tumors such as ganglioglioma [11, 12], pleomorphic xanthoastrocytoma (PXA) [13, 14] and papillary craniopharyngioma [15, 16]. The gene discussed is BRAF; the disease is pleomorphic xanthoastrocytoma.